Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Singer

Showing results (751-760 of 771) with videos related to

Pageof 78
Sort By:
American Heart Journal|September 1, 2014
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Paul L Hess, Michael J Mirro, Hans-Christoph Diener, et al.
Heart (British Cardiac Society)|September 20, 2018
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillationTaku Inohara, Sunghee Kim, Karen Pieper, et al.
Journal of the American Heart Association|February 18, 2018
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)Benjamin A Steinberg, Peter Shrader, Karen Pieper, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Journal of the American Heart Association|October 30, 2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AFJeffrey B Washam, DaJuanicia N Holmes, Laine E Thomas, et al.
Heart Rhythm O2|January 2, 2023
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillationMatthew A Carlisle, Peter Shrader, Marat Fudim, et al.
Plos One|December 10, 2016
An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in NigeriaOgbonnaya S Njoku, Mark M Manak, Robert J O'Connell, et al.
American Heart Journal|May 27, 2019
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation IITaku Inohara, Peter Shrader, Karen Pieper, et al.
Heart (British Cardiac Society)|January 9, 2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillationTaku Inohara, DaJuanicia N Holmes, Karen Pieper, et al.
The Lancet. Neurology|March 10, 2012
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFGraeme J Hankey, Manesh R Patel, Susanna R Stevens, et al.
Pageof 78

Showing results (751-760 of 771) with videos related to

Sort By:
Pageof 78
American Heart Journal|September 1, 2014
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Paul L Hess, Michael J Mirro, Hans-Christoph Diener, et al.
Heart (British Cardiac Society)|September 20, 2018
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillationTaku Inohara, Sunghee Kim, Karen Pieper, et al.
Journal of the American Heart Association|February 18, 2018
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)Benjamin A Steinberg, Peter Shrader, Karen Pieper, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Journal of the American Heart Association|October 30, 2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AFJeffrey B Washam, DaJuanicia N Holmes, Laine E Thomas, et al.
Heart Rhythm O2|January 2, 2023
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillationMatthew A Carlisle, Peter Shrader, Marat Fudim, et al.
Plos One|December 10, 2016
An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in NigeriaOgbonnaya S Njoku, Mark M Manak, Robert J O'Connell, et al.
American Heart Journal|May 27, 2019
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation IITaku Inohara, Peter Shrader, Karen Pieper, et al.
Heart (British Cardiac Society)|January 9, 2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillationTaku Inohara, DaJuanicia N Holmes, Karen Pieper, et al.
The Lancet. Neurology|March 10, 2012
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFGraeme J Hankey, Manesh R Patel, Susanna R Stevens, et al.
Pageof 78